CA2188695A1 - Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections - Google Patents
Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infectionsInfo
- Publication number
- CA2188695A1 CA2188695A1 CA002188695A CA2188695A CA2188695A1 CA 2188695 A1 CA2188695 A1 CA 2188695A1 CA 002188695 A CA002188695 A CA 002188695A CA 2188695 A CA2188695 A CA 2188695A CA 2188695 A1 CA2188695 A1 CA 2188695A1
- Authority
- CA
- Canada
- Prior art keywords
- beta
- penem
- combination
- lactam antibiotic
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000035143 Bacterial infection Diseases 0.000 title 1
- 108090000204 Dipeptidase 1 Proteins 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 title 1
- 102000006635 beta-lactamase Human genes 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000002132 β-lactam antibiotic Substances 0.000 title 1
- 229940124586 β-lactam antibiotics Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 abstract 1
- 229960003022 amoxicillin Drugs 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 229960004261 cefotaxime Drugs 0.000 abstract 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 abstract 1
- 229960000484 ceftazidime Drugs 0.000 abstract 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 abstract 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 abstract 1
- 229960002292 piperacillin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical formulation comprises, in combination with a penem of formula (I), in which: R1 is hydrogen or an organic substituent group; R2 is a fused bicyclic heterocyclic ring system of general formula (a), wherein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is zero, 1 or 2; and R3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol = /
= indicates that the double bond may be in either the E or Z configuration;
and a pharmaceutically acceptable carrier; a .beta.-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.
= indicates that the double bond may be in either the E or Z configuration;
and a pharmaceutically acceptable carrier; a .beta.-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9408161A GB9408161D0 (en) | 1994-04-25 | 1994-04-25 | Pharmaceutical formulations |
| GB9408163.5 | 1994-04-25 | ||
| GB9408164.3 | 1994-04-25 | ||
| GB9408162.7 | 1994-04-25 | ||
| GB9408161.9 | 1994-04-25 | ||
| GB9408162A GB9408162D0 (en) | 1994-04-25 | 1994-04-25 | Pharmaceutical formulations |
| GB9408164A GB9408164D0 (en) | 1994-04-25 | 1994-04-25 | Pharmaceutical formulations |
| GB9408163A GB9408163D0 (en) | 1994-04-25 | 1994-04-25 | Pharmaceutical formulations |
| PCT/EP1995/001546 WO1995028935A1 (en) | 1994-04-25 | 1995-04-22 | Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2188695A1 true CA2188695A1 (en) | 1995-11-02 |
| CA2188695C CA2188695C (en) | 2007-07-24 |
Family
ID=38325174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002188695A Expired - Fee Related CA2188695C (en) | 1994-04-25 | 1995-04-22 | Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2188695C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009114921A1 (en) * | 2008-03-17 | 2009-09-24 | Dmitrienko Gary I | INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES |
-
1995
- 1995-04-22 CA CA002188695A patent/CA2188695C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009114921A1 (en) * | 2008-03-17 | 2009-09-24 | Dmitrienko Gary I | INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2188695C (en) | 2007-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE821129L (en) | Cephalosporins | |
| MX9804107A (en) | Quinoline derivatives. | |
| AU1962892A (en) | Cephalosporin compounds, processes for their preparation and antibacterial agents | |
| MX9605149A (en) | Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections. | |
| MX9803692A (en) | Tricyclic erythromycin derivatives. | |
| GB1456144A (en) | Ureido-aryl cephalosporin compounds | |
| CA2147755A1 (en) | 6-(substituted methylene) penems and intermediates | |
| ES2001773A6 (en) | Cephalosporin derivatives. | |
| ES8104307A1 (en) | 3-[(8-Carboxy-6-tetrazolo[1,5-b]pyridazinyl)-thiomethyl]-7-[2-(2-amino-4-thiazolyl)-2-methoxyimino-acetamido]-3-cephem-4-carboxylic acid | |
| IE850475L (en) | 6-(aminoacyloxymethyl) penicillanic acid 1,1-dioxides as beta-lactamase inhibitors | |
| MY104109A (en) | Antibacterial 9-deoxo-9a-allyl and propargyl-9a-aza-9a-homoerythromycin a derivatives. | |
| CA2188695A1 (en) | Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections | |
| CA2107675A1 (en) | Antibiotic carbapenem derivatives | |
| NZ236413A (en) | Cephalosporin derivatives and pharmaceutical compositions | |
| GB9326248D0 (en) | Pharmaceutical formulations | |
| KR900005050B1 (en) | 6-beta (substituted)-(s)-hydroxymethyl-penicillanic acids and derivatives thereof | |
| NZ218227A (en) | Cephalosporin derivatives and pharmaceutical compositions | |
| TW371304B (en) | Cephem compounds having antibacterial activity, their production and pharmaceutical composition | |
| JPS5716889A (en) | Penicillanic acid-1,1-dioxide derivative, its preparation and beta-lactamase inhibitor containing the same as active principle | |
| CA2013226A1 (en) | Cephalosporin derivatives and processes for their preparation | |
| ES8703479A1 (en) | New antibiotic penicillanic acid cpds. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |